Current Approaches to the Search of Anxiolytic Drugs

Maltsev, D. V.; Spasov, A. A.; Мирошников, М. В.; Skripka, Maria O.

doi:10.1134/s1068162021030122

Cited by 3 publications

(1 citation statement)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to these and the other neurotransmitter and neuro-modulatory systems discussed above, numerous other mechanisms and targets have been proposed for their potential as anxiolytics and PTSD medications based on preclinical data but have not yet progressed to substantive clinical investigation. These include the targeting of the metabotropic glutamate receptor (mGluR) ( Ferraguti, 2018 ), melatonin ( Millan, 2022 ), cellular/mitochondrial metabolism and oxidative stress ( Bersani et al, 2020 ; Fedoce et al, 2018 ; Filiou and Sandi, 2019 ; Zalachoras et al, 2020 ), and epigenetic mechanisms ( Bonomi et al, 2022 ; Peedicayil, 2020 ; Whittle and Singewald, 2014 ), amongst others ( Maltsev et al, 2021 ; Pérez de la Mora et al, 2022 ; Raut et al, 2022b ).…”

Section: Other Systems Of Notementioning

confidence: 99%

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder

Singewald¹,

Sartori²,

Reif

et al. 2023

Neuropharmacology

View full text Add to dashboard Cite

Section: Other Systems Of Notementioning

confidence: 99%

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder

Singewald¹,

Sartori²,

Reif

et al. 2023

Neuropharmacology

View full text Add to dashboard Cite

Synthesis, Characterization, and In Vivo Evaluation of Escitalopram Analogues for Depression

Deiab,

Alqudah,

Aljaber

et al. 2023

Russ J Bioorg Chem

View full text Add to dashboard Cite

Design, Synthesis and Pharmacological Evaluation of Novel C2,C3-Quinoxaline Derivatives as Promising Anxiolytic Agents

Maltsev

Skripka

Spasov

et al. 2022

IJMS

View full text Add to dashboard Cite

A new series of quinoxaline derivatives, 2a–4b, were synthesized and their anxiolytic potential was evaluated in vivo using elevated plus maze (EPM), open field (OF) and light-dark box (LDB) techniques. According to the results of the EPM, four active compounds were found in 2a, 2b, 2c, 4b. Their anxiolytic properties were confirmed in terms of LDB and the most active was compound 2b. In the OF, only 2c had an influence on the locomotor activity of the rodents. Thus, the most promising substance was determined; this was 2b, which has the structure of 2-(2-{[3-(4-tert-butylphenyl)quinoxaline-2-yl]methyl}-4,5-dimethoxyphenyl)-N-methylethan-1-amine hydrochloride. The obtained data were analyzed with the pharmacophore feature prediction approach, which made it possible to compare the structures of the studied compounds with the reference drug diazepam, and to determine the contribution of pharmacophores to the manifestation of the activity under study. ADMET analysis was carried out for compound 2b and the acute oral toxicity of this substance was also tested in vivo. As a result of the study, a promising compound with a high anxiolytic effect and low level of toxicity 2b was found, which is of interest for further preclinical study of its properties.

show abstract

Current Approaches to the Search of Anxiolytic Drugs

Cited by 3 publications

References 113 publications

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder

Synthesis, Characterization, and In Vivo Evaluation of Escitalopram Analogues for Depression

Design, Synthesis and Pharmacological Evaluation of Novel C2,C3-Quinoxaline Derivatives as Promising Anxiolytic Agents

Contact Info

Product

Resources

About